作者: C R Nichols , P J Catalano , E D Crawford , N J Vogelzang , L H Einhorn
DOI: 10.1200/JCO.1998.16.4.1287
关键词:
摘要: PURPOSETo compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental ifosfamide, (VIP) as primary treatment of men advanced, disseminated germ cell tumors.PATIENTS AND METHODSA total 304 advanced tumors were randomly allocated receive four courses BEP or VIP. Two hundred ninety-nine patients assessable for toxicity 286 response. Complete response rates, favorable (complete remission, surgical free disease, continuous partial remission 2+ years), time failure, overall survival assessed.RESULTSOverall complete rate (VIP, 37%; BEP, 31%), 63%; 60%), failure-free at 2 years 64%; 2-year 74%; 71%) not significantly different between the two treatments. Grade 3 worse toxicity, particularly hematologic genitourinary was sig...